$LQDA

SINGH RAMAN sold $1.8M of LQDA

SINGH RAMAN sold 29,494 shares of Liquidia Corp (LQDA) at $60.13 ($1.77M total) on 2026-05-21.

Original reporting
SEC EDGAR · SINGH RAMAN
Published May 26, 2026, 10:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishMed
01

Why it matters

The disclosure may influence short-term trading sentiment, but it does not introduce new company-specific catalysts (no earnings, trial, deal, or regulatory action mentioned).

02

Market read

Traders may monitor LQDA for follow-through selling/insider activity, but fundamentals are unchanged based on this filing alone.

03

What to watch

The sale is not explicitly tied to a 10b5-1 plan; without context on prior grants/vesting or total holdings history, directional inference is weak.

Relevance 8/10Timing: Immediate (today’s SEC Form 4 filing may affect intraday sentiment/flow).

Background

The article is a SEC Form 4 insider transaction disclosure for Liquidia Corp, filed on 2026-05-26.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia director Singh Raman filed an open-market sale of 29,494 shares (~$1.77M) on 2026-05-21 via SEC Form 4.

Expected impact

Likely modest, short-lived downside/volatility around the filing; no strong directional signal without follow-on news.

Evidence & confidence

This is a routine Form 4 disclosure with no stated reason, no 10b5-1 plan, and no accompanying operational/clinical update in the article.

Market effects

Limited read-across; insider sales are company-specific unless paired with broader sector catalysts.

None indicated; this is a US-listed issuer’s insider transaction.

None indicated.

Counterpoint

Director selling can be driven by diversification, tax planning, or personal liquidity needs rather than bearish expectations.

Key entities

  • Liquidia Corp

    Subject of the SEC Form 4 insider sale by a director (Singh Raman).

  • Singh Raman

    Director who sold 29,494 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.